SuperworthPelthos Therapeutics PTHS
- Market cap
- $65.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $43.3M
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Pelthos Therapeutics trades at 1.5× sales. Revenue was $43.3M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | $7.4M | $9.4M | $10.9M | $15.6M | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | $2.3M | $1.7M | $1.7M | $3.6M |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | $5.1M | $7.7M | $9.2M | $12M |
| R&D | $49.1K | $2.3M | $466.6K+151% | $13K−74% | $414.6K+744% | $285.2K−88% | $194.3K−58% | $514.8K+3874% | $145K−65% | $374K+31% | $186K−4% | $600K+17% |
| SG&A | $661.6K | $1.1M | $787.6K+65% | $1.2M+125% | $1.6M+147% | $1.5M+45% | $1.6M+108% | $2.7M+125% | $19.6M+1101% | $18.5M+1100% | $21.1M+1187% | $27.7M+919% |
| −$1.3M | −$3.9M | −$1.9M+112% | −$1.8M+127% | −$2M+59% | −$1.8M−53% | −$1.8M−5% | −$3.2M+83% | −$15.4M+650% | −$12M+558% | −$13.1M+614% | −$17.3M+436% | |
| Interest expense | $130K | $160.3K | $628.3K+1109% | $11.1K−94% | $39K−70% | $108K−33% | $133.6K−79% | $218K+1871% | $1.3M+3350% | $1.3M+1117% | $2.4M+1661% | $2.4M+996% |
| Pre-tax income | −$1.4M | −$4M | −$2.6M+165% | −$1.8M+86% | −$1.7M+19% | −$1.9M−52% | −$2M−23% | −$3.4M+95% | −$16.7M+886% | −$28.6M+1384% | −$25.1M+1174% | −$23.4M+579% |
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | −$465K | −$6.9M | $0 | $0 | |
| Net income | −$1.4M | −$4M | −$2.6M+165% | −$1.8M+86% | −$1.7M+19% | −$1.9M−52% | −$2M−23% | −$3.4M+95% | n/a | n/a | −$25.1M+1174% | −$23.4M+579% |
| n/a | n/a | −$5.50 | −$3.07 | −$2.93 | −$3.19 | −$3.21−42% | −$5.29+72% | n/a | n/a | −$7.57+136% | −$6.62+25% | |
| n/a | n/a | 469.1K | 577.4K | 579.2K | 603.3K | 612.9K+31% | 651.9K+13% | 3.1M+429% | 3.2M+425% | 3.3M+440% | 3.5M+443% |
Gross profit: 6 periods, Q1 FY25 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 4 periods, Q1 FY24 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Pelthos Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PTHSPelthos Therapeutics | $65.1M | n/m | n/a | 1.5× | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Pelthos Therapeutics
Each number over time
Where it ranks
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .